Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bausch Health Companies Inc. T.BHC

Alternate Symbol(s):  BHC

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:Bausch + Lomb Reports

It would be nice to see some profits instead.  rate and reply

Bausch + Lomb Reports

VAUGHAN, ON and LAVAL, QC and TRENTON, N.J., April 21, 2022 /CNW/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: more

Sending proposals for June 14, 2022 AGM

Just saw that shareholders are able to send proposals for the upcoming AGM but have no idea on how to execute for this. How does one go about summiting proposals to BHC?  rate and reply

Pricing Of Private Offering Of Senior Secured Notes

LAVAL, QC, Jan. 27, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its more

APMA Grants Seal of Approval for JUBLIA® (efinaconazole)

LAVAL, QC, Dec. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the more

To Reduce Debt By $350 Million

LAVAL, Quebec, Aug. 3, 2021 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $ more

Possible buy out?

I'm surprised that BHC hasn't made a move on Voyageur Pharmaceuticals!  rate and reply